Gastrointestinal endoscopy · 2013
Prevalence of malignancy in patients with pure main duct intraductal papillary mucinous neoplasms.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Abdeljawad Khaled, Vemulapalli Krishna C, Schmidt C Max, Dewitt John, Sherman Stuart, Imperiale Thomas F, Al-Haddad Mohammad
Аннотация
BACKGROUND: Risk of malignancy in main duct intraductal papillary mucinous neoplasm (MD-IPMN) ranges from 36% to 100% in the literature. Although surgical resection is recommended for all MD-IPMNs, the risk of malignancy based on main pancreatic duct (MPD) size alone remains unclear.
OBJECTIVE: To assess the prevalence of malignancy in symptomatic and asymptomatic patients with pure MD-IPMN based on MPD size.
DESIGN: Single-center retrospective study of prospectively collected data.
SETTINGS: Tertiary referral center.
PATIENTS AND INTERVENTIONS: Fifty-two patients with pure low-risk MD-IPMN. Clinical, endoscopic, radiographic, and pathologic data were reviewed.
MAIN OUTCOME MEASUREMENTS: Prevalence of malignancy in patients with pure MD-IPMN based on histopathology of resected lesions.
RESULTS: Sixteen asymptomatic patients had pure MD-IPMN on surgical pathology, 4 (25%) with malignant disease, compared with 25 of 36 symptomatic patients (69%) with pure MD-IPMN. Logistic regression identified symptoms and MPD size as predictors of malignancy. Receiver operating characteristic curve analysis demonstrated that MPD size (optimal cutoff of 8 mm) produced the greatest area under the curve to discriminate between benign and malignant MD-IPMN (.83; 95% CI, .72-.94). MPD size greater than 8 mm has a relative risk of 2.8 for malignancy (95% CI, 1.6-4.9).
LIMITATIONS: Retrospective, single-center study at a tertiary referral hospital. Study population included only patients who underwent surgical resection.
CONCLUSION: Asymptomatic MD-IPMN patients with a duct size of no more than 8 mm have a lower prevalence of malignancy and may represent a distinct group of patients with less aggressive biologic behavior. Further studies are needed to confirm our observations.
OBJECTIVE: To assess the prevalence of malignancy in symptomatic and asymptomatic patients with pure MD-IPMN based on MPD size.
DESIGN: Single-center retrospective study of prospectively collected data.
SETTINGS: Tertiary referral center.
PATIENTS AND INTERVENTIONS: Fifty-two patients with pure low-risk MD-IPMN. Clinical, endoscopic, radiographic, and pathologic data were reviewed.
MAIN OUTCOME MEASUREMENTS: Prevalence of malignancy in patients with pure MD-IPMN based on histopathology of resected lesions.
RESULTS: Sixteen asymptomatic patients had pure MD-IPMN on surgical pathology, 4 (25%) with malignant disease, compared with 25 of 36 symptomatic patients (69%) with pure MD-IPMN. Logistic regression identified symptoms and MPD size as predictors of malignancy. Receiver operating characteristic curve analysis demonstrated that MPD size (optimal cutoff of 8 mm) produced the greatest area under the curve to discriminate between benign and malignant MD-IPMN (.83; 95% CI, .72-.94). MPD size greater than 8 mm has a relative risk of 2.8 for malignancy (95% CI, 1.6-4.9).
LIMITATIONS: Retrospective, single-center study at a tertiary referral hospital. Study population included only patients who underwent surgical resection.
CONCLUSION: Asymptomatic MD-IPMN patients with a duct size of no more than 8 mm have a lower prevalence of malignancy and may represent a distinct group of patients with less aggressive biologic behavior. Further studies are needed to confirm our observations.